CN108653667A - 一种复方甘草酸单铵s注射液药物组合物及其制备方法和应用 - Google Patents
一种复方甘草酸单铵s注射液药物组合物及其制备方法和应用 Download PDFInfo
- Publication number
- CN108653667A CN108653667A CN201810631103.6A CN201810631103A CN108653667A CN 108653667 A CN108653667 A CN 108653667A CN 201810631103 A CN201810631103 A CN 201810631103A CN 108653667 A CN108653667 A CN 108653667A
- Authority
- CN
- China
- Prior art keywords
- injection
- pharmaceutical composition
- water
- monoammonium glycyrrhizinate
- glycyrrhizinate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000007924 injection Substances 0.000 title claims abstract description 60
- 238000002347 injection Methods 0.000 title claims abstract description 60
- -1 compound monoammonium glycyrrhizinate Chemical class 0.000 title claims abstract description 43
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 35
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 60
- 239000003814 drug Substances 0.000 claims abstract description 52
- 239000000284 extract Substances 0.000 claims abstract description 48
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract description 42
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 42
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 38
- 239000008215 water for injection Substances 0.000 claims abstract description 37
- ILRKKHJEINIICQ-OOFFSTKBSA-N Monoammonium glycyrrhizinate Chemical compound N.O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O ILRKKHJEINIICQ-OOFFSTKBSA-N 0.000 claims abstract description 28
- 238000000605 extraction Methods 0.000 claims abstract description 27
- 239000007788 liquid Substances 0.000 claims abstract description 26
- 239000004471 Glycine Substances 0.000 claims abstract description 21
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 claims abstract description 20
- 229960001305 cysteine hydrochloride Drugs 0.000 claims abstract description 20
- 238000010992 reflux Methods 0.000 claims abstract description 20
- 239000011780 sodium chloride Substances 0.000 claims abstract description 19
- 238000011049 filling Methods 0.000 claims abstract description 18
- 238000007789 sealing Methods 0.000 claims abstract description 16
- 239000001509 sodium citrate Substances 0.000 claims abstract description 15
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims abstract description 15
- 238000001914 filtration Methods 0.000 claims abstract description 13
- 210000004185 liver Anatomy 0.000 claims abstract description 13
- 238000005303 weighing Methods 0.000 claims abstract description 11
- 229940079593 drug Drugs 0.000 claims abstract description 10
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 claims abstract description 9
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229940101006 anhydrous sodium sulfite Drugs 0.000 claims abstract description 7
- 208000006454 hepatitis Diseases 0.000 claims abstract description 7
- 229960002449 glycine Drugs 0.000 claims abstract description 6
- 230000004064 dysfunction Effects 0.000 claims abstract description 4
- 239000000243 solution Substances 0.000 claims description 28
- 239000003610 charcoal Substances 0.000 claims description 25
- 238000003756 stirring Methods 0.000 claims description 25
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 22
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 10
- 238000013019 agitation Methods 0.000 claims description 10
- 239000003643 water by type Substances 0.000 claims description 10
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 claims description 9
- 239000002253 acid Substances 0.000 claims description 9
- 239000000706 filtrate Substances 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 239000002994 raw material Substances 0.000 claims description 7
- 241000202726 Bupleurum Species 0.000 claims description 6
- 241000972672 Phellodendron Species 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- 238000012545 processing Methods 0.000 claims description 6
- 235000010265 sodium sulphite Nutrition 0.000 claims description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 5
- 230000001580 bacterial effect Effects 0.000 claims description 5
- 229940126678 chinese medicines Drugs 0.000 claims description 5
- 238000005261 decarburization Methods 0.000 claims description 5
- 238000000151 deposition Methods 0.000 claims description 5
- 239000012530 fluid Substances 0.000 claims description 5
- 239000012528 membrane Substances 0.000 claims description 5
- 229910052757 nitrogen Inorganic materials 0.000 claims description 5
- 239000011734 sodium Substances 0.000 claims description 5
- 229910052708 sodium Inorganic materials 0.000 claims description 5
- 229910001220 stainless steel Inorganic materials 0.000 claims description 5
- 239000010935 stainless steel Substances 0.000 claims description 5
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 claims description 5
- 238000009736 wetting Methods 0.000 claims description 5
- 241000334160 Isatis Species 0.000 claims description 4
- 208000005374 Poisoning Diseases 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 238000012856 packing Methods 0.000 claims description 3
- 231100000572 poisoning Toxicity 0.000 claims description 3
- 230000000607 poisoning effect Effects 0.000 claims description 3
- 208000008964 Chemical and Drug Induced Liver Injury Diseases 0.000 claims description 2
- 206010008909 Chronic Hepatitis Diseases 0.000 claims description 2
- 206010013700 Drug hypersensitivity Diseases 0.000 claims description 2
- 231100000354 acute hepatitis Toxicity 0.000 claims description 2
- 201000005311 drug allergy Diseases 0.000 claims description 2
- 210000001508 eye Anatomy 0.000 claims description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims 2
- 229960001484 edetic acid Drugs 0.000 claims 2
- 235000015424 sodium Nutrition 0.000 claims 2
- OGMADIBCHLQMIP-UHFFFAOYSA-N 2-aminoethanethiol;hydron;chloride Chemical compound Cl.NCCS OGMADIBCHLQMIP-UHFFFAOYSA-N 0.000 claims 1
- 206010070863 Toxicity to various agents Diseases 0.000 claims 1
- 238000002386 leaching Methods 0.000 claims 1
- 229910052938 sodium sulfate Inorganic materials 0.000 claims 1
- 235000011152 sodium sulphate Nutrition 0.000 claims 1
- 230000000857 drug effect Effects 0.000 abstract description 6
- 231100000283 hepatitis Toxicity 0.000 abstract description 3
- 239000002245 particle Substances 0.000 abstract description 3
- 230000001225 therapeutic effect Effects 0.000 abstract description 3
- 230000001684 chronic effect Effects 0.000 abstract description 2
- 238000002156 mixing Methods 0.000 abstract description 2
- 230000002085 persistent effect Effects 0.000 abstract description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 15
- 230000000694 effects Effects 0.000 description 9
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 8
- 230000008859 change Effects 0.000 description 6
- 239000013618 particulate matter Substances 0.000 description 5
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 231100000753 hepatic injury Toxicity 0.000 description 4
- 239000003549 soybean oil Substances 0.000 description 4
- 235000012424 soybean oil Nutrition 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000007928 intraperitoneal injection Substances 0.000 description 3
- 210000005228 liver tissue Anatomy 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 2
- 239000010231 banlangen Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 241001582888 Lobus Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000007380 fibre production Methods 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229940001482 sodium sulfite Drugs 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/19—Acanthaceae (Acanthus family)
- A61K36/195—Strobilanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/233—Bupleurum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
- A61K36/315—Isatis, e.g. Dyer's woad
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/756—Phellodendron, e.g. corktree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明涉及药物技术领域,具体涉及一种复方甘草酸单铵S注射液药物组合物及其制备方法和应用,该药物组合物包括甘草酸单铵盐S、盐酸半胱氨酸、甘氨酸、无水亚硫酸钠、依地酸二钠、氯化钠、柠檬酸钠,柠檬酸和中药提取物,最后用注射用水定容至,该药物组合物的制备步骤包括称量粉碎、回流提取、混合配液、除菌过滤和灌装封口,可应用在急、慢性,迁延型肝炎引起的肝功能异常中的治疗中,本发明不仅增强了药剂的治疗效果和稳定性,而且能使药剂中粒子的溶解度更好,使本注射液药物组合物的安全性更好,药效更佳,减小用药量,增加患者服药安全性。
Description
技术领域
本发明涉及药物技术领域,特别涉及一种复方甘草酸单铵S注射液药物组合物及其制备方法和应用。
背景技术
复方甘草酸单铵中的甘草酸单铵具有很强的保护肝细胞的作用,复方甘草酸单铵被广泛应用到急、慢性,迁延型肝炎引起的肝功能异常的治疗中,同时也应用到中毒性肝炎、外伤性肝炎和癌症的辅助治疗中。现有的复方甘草酸单铵在临床上的应用主要注射液和冻干粉两种形式,但目前在应用中的复方甘草酸单铵制剂差次不齐,多数普遍存在稳定性不好的问题,为加强该药剂的稳定性,目前的多数药剂都是通过往其中加入稳定剂来实现的,虽然稳定剂的加入改善了药剂的稳定性,但同时也会导致药剂中产生不易发现的不溶性微粒,这些微粒具有潜在的副作用,严重影响人体的健康因此急需研发新型的稳定、安全的复方甘草酸单铵制剂;同时现在复方甘草酸单铵制剂主要的药物活性成分,主要都以甘草酸单铵为活性成分,效果和疗效较为单一,治疗时,多需与其它药物联合使用,增大了患者的用药量和用药风险,开发联合其它药物的复方甘草酸单铵的制剂,可以满足患者临床治疗的需要,减少其用药风险和用药量,并有利于增强其疗效和适用范围,能更好地服务于广大患者人群。
发明内容
为了克服现有大部分甘草酸单铵S注射液存在的不足,本发明提出了一种复方甘草酸单铵S注射液药物组合物及其制备方法和应用;本发明提供的复方甘草酸单铵S注射液药物组合物通过将甘草酸单铵与中药进行联合使用,这样不仅能增强注射液的药效,也能增加治疗的适用症状,而且,可以减少患者的服药量,增加患者服药安全性。
为了实现上述目的,本发明所采用的技术方案是:
一种复方甘草酸单铵S注射液药物组合物,包括以下重量份的原料:
400-600g甘草酸单铵盐S、300-500g盐酸半胱氨酸、4.0-6.0kg甘氨酸、400-650g无水亚硫酸钠、40-60g依地酸二钠、1.0-3.0kg氯化钠、柠檬酸钠30~150g,柠檬酸20~120g,250~500ml中药提取物,最后用注射用水定容至180-450L。
优选的,一种复方甘草酸单铵S注射液药物组合物,包括以下重量份的原料:
450g甘草酸单铵盐S、360g盐酸半胱氨酸、4.5kg甘氨酸、500g无水亚硫酸钠、45g依地酸二钠、1.2kg氯化钠、柠檬酸钠50g,柠檬酸40g和320ml中药提取物,最后用注射用水定容至220L。
优选地,所述的中药提取物包含茵陈提取物、柴胡提取物、郁金提取物、板蓝根提取物和黄柏提取物中的一种或多种的混合物,所述中药提取物为将相关中药粉碎后,进行混合,再在70~85℃条件下,用注射用水进行回流提取1~2.5小时,取初次提取液;随后,再将药渣进行二次提取,在65~80℃条件下,再用注射用水回流提取1~2小时;弃滤渣,取滤液;合并两次提取液,并进行浓缩。
更优选地,所述的中药提取物包含茵陈提取物、柴胡提取物、郁金提取物、板蓝根提取物和黄柏提取物,所述中药提取物为将相关中药粉碎后,进行混合,再在75℃条件下,用注射用水进行回流提取1.5小时,取初次提取液;随后,再将药渣进行二次提取,在65℃条件下,再用注射用水回流提取1小时;弃滤渣,取滤液;合并两次提取液,并进行浓缩。
优选地,一种复方甘草酸单铵S注射液药物组合物的制备方法,其特征在于,包括以下步骤:
S1、分别将甘草酸单铵盐S、盐酸半胱氨酸、甘氨酸、柠檬酸钠、无水亚硫酸钠、依地酸二钠、柠檬酸、氯化钠和中药材进行称量;活性炭需先在存炭称炭室内进行称炭和溶炭处理,即用称量杯称量药用炭后加入适量注射用水,搅拌润湿;
S2、将称量好的各种中药材进行粉碎、过筛并混合;随后,再在70~85℃条件下,用注射用水对混合的中药材进行回流提取,时间1~2.5小时,取提取液;随后,再将药渣进行二次提取,在65~80℃条件下,再用注射用水回流提取1~2小时;弃滤渣,取滤液;合并两次提取液,并用过滤膜进行过滤,过滤完成后进行浓缩;
S3、再向配液罐中加入100L注射用水和中药提取液,并搅拌3min,然后再依次往里加入依地酸二钠、氯化钠、甘氨酸、柠檬酸、柠檬酸钠,边加入边搅拌5min,全部溶解后再加入浸湿的活性炭,搅拌吸附20min后分别通过钛棒过滤器和过滤器进行脱碳和过滤处理;
S4、向配液罐分次加入注射用水,并不断搅拌,并将溶液的PH值调节至6.6~7.1,然后往灭菌过的不锈钢桶里加10L注射用水将甘草酸单铵盐S、盐酸半胱氨酸、无水亚硫酸钠溶解后加入稀配罐,最后用注射用水将溶液调整至220L,循环搅拌20min后将药液温度控制在30~40℃,并将药液的pH值调节至5.8~7.2,各项指标合格后向稀配罐中充氮气进行保护;
S5、将稀配处理后的药液通过除菌滤器过滤后,打入缓冲罐;
S6、通过灌装封口机对药液进行灌装封口处理,灌装封口的标准为2.05~2.15ml/支。
优选地,所述的步骤S1-S6的操作环境为:相对湿度:50~65%,温度:15~25℃;使用的注射用水在使用时需将温度维持在50~65℃。
优选地,所述的包装规格为2ml×10支/盒×400盒/箱;所述的过滤膜为的滤孔孔径为8~12μm。
优选地,所述的灌装指标合格的标准为:药液为无色的或淡黄色澄明液体,不得有见肉眼可见异物,甘草酸单铵盐的浓度为1.82~2.13mg/ml;甘氨酸的浓度为18.5~21.5mg/ml、盐酸半胱氨酸的浓度为1.50~1.65mg/ml。
优选地,所述的工序S3至工序S5需在12个小时内完成;工序S6需在10小时之内完成。
优选地,所述的一种复方甘草酸单铵S注射液药物组合物用于制备急、慢性肝炎引起的肝功能异常和中毒性肝炎的辅助的治疗药物中的应用。
优选地,所述的一种复方甘草酸单铵S注射液药物组合物用于食物中毒、药物中毒、药物过敏的药物中的应用。
与现有技术相比,本发明的有益效果是:
(1)本发明的复方甘草酸单铵S注射液药物组合物通过将甘草酸单铵盐与甘氨酸、盐酸半胱氨酸、柠檬酸、柠檬酸钠等辅助成分进行科学配伍、合理搭配,再往其中添加中药提取液、柠檬酸和柠檬酸钠、氯化钠和活性炭改良成分,不仅提高了药剂的稳定性,而且能增强药效,疗效更显著;
(2)通过稳定性实验发现,本发明的复方甘草酸单铵S注射液药物组合物在放置一段时间后药液的浑浊度没有明显变化,显微镜下也观察不到不溶性微粒的存在,不仅稳定性好,而且不产生不溶性微粒,安全性好。
具体实施方式
下面对本发明的具体实施方式作进一步说明。在此需要说明的是,对于这些实施方式的说明用于帮助理解本发明,但并不构成对本发明的限定。此外,下面所描述的本发明各个实施方式中所涉及的技术特征只要彼此之间未构成冲突就可以相互组合。
实施例1:
一种复方甘草酸单铵S注射液药物组合物,包括以下重量份的原料:
400g甘草酸单铵盐S、320g盐酸半胱氨酸、4.0kg甘氨酸、400g无水亚硫酸钠、45g依地酸二钠、1.0kg氯化钠、柠檬酸钠30g,柠檬酸21g,280ml由茵陈提取物、柴胡提取物、郁金提取物、板蓝根提取物和黄柏提取物回流提取制得的中药提取液,最后用注射用水定容至200L。
该种复方甘草酸单铵S注射液药物组合物的制备方法,包括以下步骤:
S1、分别将甘草酸单铵盐S、盐酸半胱氨酸、甘氨酸、柠檬酸钠、无水亚硫酸钠、依地酸二钠、柠檬酸、氯化钠和中药材进行称量;活性炭需先在存炭称炭室内进行称炭和溶炭处理,即用称量杯称量药用炭后加入适量注射用水,搅拌润湿;
S2、将称量好的各种中药材进行粉碎、过筛并混合;随后,再在75℃条件下,用注射用水对混合的中药材进行回流提取,时间1.5小时,取提取液;随后,再将药渣进行二次提取,在65℃条件下,再用注射用水回流提取1小时;弃滤渣,取滤液;合并两次提取液,并用过滤膜进行过滤,过滤完成后进行浓缩;
S3、再向配液罐中加入100L注射用水和中药提取液,并搅拌3min,然后再依次往里加入依地酸二钠、氯化钠、甘氨酸、柠檬酸、柠檬酸钠,边加入边搅拌5min,全部溶解后再加入浸湿的活性炭,搅拌吸附20min后分别通过钛棒过滤器和过滤器进行脱碳和过滤处理;
S4、向配液罐分次加入注射用水,并不断搅拌,并将溶液的PH值调节至6.6~7.1,然后往灭菌过的不锈钢桶里加10L注射用水将甘草酸单铵盐S、盐酸半胱氨酸、无水亚硫酸钠溶解后加入稀配罐,最后用注射用水将溶液调整至220L,循环搅拌20min后将药液温度控制在35℃,并将药液的pH值调节至5.8~7.2,各项指标合格后向稀配罐中充氮气进行保护;
S5、将稀配处理后的药液通过除菌滤器过滤后,打入缓冲罐;
S6、通过灌装封口机对药液进行灌装封口处理,灌装封口的标准为2.05~2.15ml/支。
实施例2:
一种复方甘草酸单铵S注射液药物组合物,包括以下重量份的原料:
430g甘草酸单铵盐S、300g盐酸半胱氨酸、4.2kg甘氨酸、450g无水亚硫酸钠、40g依地酸二钠、1.2kg氯化钠、柠檬酸钠40g,柠檬酸25g,300ml由茵陈提取物、柴胡提取物、郁金提取物、板蓝根提取物和黄柏提取物回流提取制得的中药提取液,最后用注射用水定容至210L。
一种复方甘草酸单铵S注射液药物组合物的制备方法,其特征在于,包括以下步骤:
S1、分别将甘草酸单铵盐S、盐酸半胱氨酸、甘氨酸、柠檬酸钠、无水亚硫酸钠、依地酸二钠、柠檬酸、氯化钠和中药材进行称量;活性炭需先在存炭称炭室内进行称炭和溶炭处理,即用称量杯称量药用炭后加入适量注射用水,搅拌润湿;
S2、将称量好的各种中药材进行粉碎、过筛并混合;随后,再在75℃条件下,用注射用水对混合的中药材进行回流提取,时间2小时,取提取液;随后,再将药渣进行二次提取,在70℃条件下,再用注射用水回流提取2小时;弃滤渣,取滤液;合并两次提取液,并用过滤膜进行过滤,过滤完成后进行浓缩;
S3、再向配液罐中加入100L注射用水和中药提取液,并搅拌3min,然后再依次往里加入依地酸二钠、氯化钠、甘氨酸、柠檬酸、柠檬酸钠,边加入边搅拌5min,全部溶解后再加入浸湿的活性炭,搅拌吸附20min后分别通过钛棒过滤器和过滤器进行脱碳和过滤处理;
S4、向配液罐分次加入注射用水,并不断搅拌,并将溶液的PH值调节至6.6~7.1,然后往灭菌过的不锈钢桶里加10L注射用水将甘草酸单铵盐S、盐酸半胱氨酸、无水亚硫酸钠溶解后加入稀配罐,最后用注射用水将溶液调整至220L,循环搅拌20min后将药液温度控制在35℃,并将药液的pH值调节至5.8~7.2,各项指标合格后向稀配罐中充氮气进行保护;
S5、将稀配处理后的药液通过除菌滤器过滤后,打入缓冲罐;
S6、通过灌装封口机对药液进行灌装封口处理,灌装封口的标准为2.05~2.15ml/支。
实施例3:
一种复方甘草酸单铵S注射液药物组合物,包括以下重量份的原料:
500g甘草酸单铵盐S、400g盐酸半胱氨酸、4.5kg甘氨酸、500g无水亚硫酸钠、50g依地酸二钠、1.5kg氯化钠、柠檬酸钠60g,柠檬酸50g,350ml由茵陈提取物、柴胡提取物、郁金提取物、板蓝根提取物和黄柏提取物回流提取制得的中药提取液,最后用注射用水定容至280L。
一种复方甘草酸单铵S注射液药物组合物的制备方法,其特征在于,包括以下步骤:
S1、分别将甘草酸单铵盐S、盐酸半胱氨酸、甘氨酸、柠檬酸钠、无水亚硫酸钠、依地酸二钠、柠檬酸、氯化钠和中药材进行称量;活性炭需先在存炭称炭室内进行称炭和溶炭处理,即用称量杯称量药用炭后加入适量注射用水,搅拌润湿;
S2、将称量好的各种中药材进行粉碎、过筛并混合;随后,再在75℃条件下,用注射用水对混合的中药材进行回流提取,时间2小时,取提取液;随后,再将药渣进行二次提取,在75℃条件下,再用注射用水回流提取2小时;弃滤渣,取滤液;合并两次提取液,并用过滤膜进行过滤,过滤完成后进行浓缩;
S3、再向配液罐中加入100L注射用水和中药提取液,并搅拌3min,然后再依次往里加入依地酸二钠、氯化钠、甘氨酸、柠檬酸、柠檬酸钠,边加入边搅拌5min,全部溶解后再加入浸湿的活性炭,搅拌吸附20min后分别通过钛棒过滤器和过滤器进行脱碳和过滤处理;
S4、向配液罐分次加入注射用水,并不断搅拌,并将溶液的PH值调节至6.6~7.1,然后往灭菌过的不锈钢桶里加10L注射用水将甘草酸单铵盐S、盐酸半胱氨酸、无水亚硫酸钠溶解后加入稀配罐,最后用注射用水将溶液调整至220L,循环搅拌20min后将药液温度控制在35℃,并将药液的pH值调节至5.8~7.2,各项指标合格后向稀配罐中充氮气进行保护;
S5、将稀配处理后的药液通过除菌滤器过滤后,打入缓冲罐;
S6、通过灌装封口机对药液进行灌装封口处理,灌装封口的标准为2.05~2.15ml/支。
药效验证:
为了进一步说明本发明的复方甘草酸单铵S注射液药物组合物的应用价值,对本发明各个实施例中药剂的稳定性和药效进行了验证,验证结果如下:
1、稳定性实验:
将按实施例1、实施例2和实施例3中的配方所制得的药剂在-20℃下分别放置3、6、9、12和15个月,观察药剂的浑浊度和不溶性微粒数量的变化,观察结果表明,这些药剂放置一段时间后药液的浑浊度没有明显变化,显微镜下也观察不到不溶性微粒的存在,表明本发明的复方甘草酸单铵S注射液药物组合物不仅稳定性好,而且不产生不溶性微粒,安全性好。
2、药效实验:
1.试验动物准备
取生长状况和大小重量相当的小白鼠60只,每组10只,分成6组,分别为:正常对照组:对改组小鼠按照日常正常饲养即可,一共饲养14周,其中在第8周后处死其中3只小白鼠;溶剂对照组:10只小白鼠,腹腔注射大豆油(0.18ml/只/次),每周3次,一共14周,在第8周后处死其中3只小白鼠;模型对照组:10只小白鼠,腹腔注射四氯化碳0.025ml(用大豆油1:6稀释),每周3次,一共14周,在第8周后处死3只小白鼠;本实施例组:10只小白鼠,腹腔注射四氯化碳0.025ml(用花生油1:6稀释),每周3次,一共14周,于第9周其对其注射本实施例注射液,每周2次,一共6周;市售其它著名品牌的复方甘草酸单铵S注射液:10只小白鼠,腹腔注射四氯化碳0.025ml(用大豆油1:6稀释),每周3次,一共14周,于第9周起注射市售其它著名品牌的复方甘草酸单铵S注射液,每周2次,共6周;其它治疗肝纤维化损伤的药物组:10只小白鼠,腹腔注射四氯化碳0.025ml(用大豆油1:6稀释),每周3次,一共14周,于第9周起按注射该药物,每周2次,共6周。
动物实验结束后,试管编号,对摘眼球取血法取血,置于未加抗凝剂的普通干净玻璃试管中,静置使其充分凝固,离心分离血清,置于-20℃条件下保存,剖开小白鼠暴露肝脏,留取肝脏右叶,其它肝脏组织部分保存待检。
造模结果:对第8周正常与模型组小白鼠,模型组小白鼠肝脏颜色偏暗、表面油腻、欠光滑、有结节;血清中的ALT、AST等相关指标明显增长;切片中的肝脏有纤维生产,显示造模成功。
1.对各组小白鼠的肝功能指标(ALT、AST和ALB)变化情况进行检测
对上述造模成功的各组的小白鼠的肝功能指标(ALT、AST和ALB)变化情况进行检测,相关检测情况如表1所示。
表1 ALT、AST和ALB变化情况表
上述试验数据结果显示,与正常组合溶剂组相比,模型组的AST和ALT都明显升高,而ALB略有下降,具有统计学意义;而本实施例组、市售其它甘草酸单铵S注射液组和市售其它治疗肝损伤注射液组与模型组相比,其AST和ALT都有明显下降,而ALB略有上升,具有统计学意义,并且本实施例组的ALT和AST下降最为明显,降幅均大于市售其它甘草酸单铵S注射液组合和市售其它治疗肝损伤注射液组,表明其治疗相关肝脏纤维化损伤的效果最为明显,治疗效果也最好,表明将甘草酸单铵S与中药做成混合制剂可以增强其药效和治疗效果。
2.新鲜肝脏组织的SOD、MDA和Hyp的比较
对各组小白鼠的肝脏的新鲜肝脏组织的SOD、MDA和Hyp等相关指标进行检测,相关检测结果和数据如表2所示。
表2新鲜肝脏组织的SOD、MDA和Hyp对比情况表
上述数据显示与正常组和溶剂组相比,模型组的MDA和Hyp明显上升,SOD下降明显,其中实施例组、市售其它复方甘草酸单铵S组合市售其它治疗肝损伤注射液组于模型组相比,SOD有明显上升,MDA和Hyp明显降低,这表明其对于小白鼠肝脏具有保护治疗效果,其中本实施例组与市售其它复方甘草酸单铵S组合市售其它治疗肝损伤注射液组相比它的SOD上升更多,MDA和Hyp下降也更明显,这显示本实施例组注射液通过将复方甘草酸单铵S与中药做成相关制剂,效果更好。
以上对本发明的实施方式作了详细说明,但本发明不限于所描述的实施方式。对于本领域的技术人员而言,在不脱离本发明原理和精神的情况下,对这些实施方式进行多种变化、修改、替换和变型,仍落入本发明的保护范围内。
Claims (10)
1.一种复方甘草酸单铵S注射液药物组合物,其特征在于:包括以下重量份的原料:
400-600g甘草酸单铵盐S、300-500g盐酸半胱氨酸、4.0-6.0kg甘氨酸、400-650g无水亚硫酸钠、40-60g依地酸二钠、1.0-3.0kg氯化钠、柠檬酸钠30~150g,柠檬酸20~120g,250~500ml中药提取物,最后用注射用水定容至180-450L。
2.根据权利要求1所述的一种复方甘草酸单铵S注射液药物组合物,其特征在于:包括以下重量份的原料:
450g甘草酸单铵盐S、360g盐酸半胱氨酸、4.5kg甘氨酸、500g无水亚硫酸钠、45g依地酸二钠、1.2kg氯化钠、柠檬酸钠50g,柠檬酸40g和320ml中药提取物,最后将注射用水定容至220L。
3.根据权利要求1所述的一种复方甘草酸单铵S注射液药物组合物,其特征在于,所述的中药提取物包含茵陈提取物、柴胡提取物、郁金提取物、板蓝根提取物和黄柏提取物中的一种或多种的混合物,所述中药提取物为将相关中药粉碎后,进行混合,再在70~85℃条件下,用注射用水进行回流提取1~2.5小时,取初次提取液;随后,再将药渣进行二次提取,在65~80℃条件下,再用注射用水回流提取1~2小时;弃滤渣,取滤液;合并两次提取液,并进行浓缩。
4.根据权利要求1所述的一种复方甘草酸单铵S注射液药物组合物的制备方法,其特征在于,包括以下步骤:
S1、分别将甘草酸单铵盐S、盐酸半胱氨酸、甘氨酸、柠檬酸钠、无水亚硫酸钠、依地酸二钠、柠檬酸、氯化钠和中药材进行称量;活性炭需先在存炭称炭室内进行称炭和溶炭处理,即用称量杯称量药用炭后加入适量注射用水,搅拌润湿;
S2、将称量好的各种中药材进行粉碎、过筛并混合;随后,再在70~85℃条件下,用注射用水对混合的中药材进行回流提取,时间1~2.5小时,取提取液;随后,再将药渣进行二次提取,在65~80℃条件下,再用注射用水回流提取1~2小时;弃滤渣,取滤液;合并两次提取液,并用过滤膜进行过滤,过滤完成后进行浓缩;
S3、先向配液罐中加入100L注射用水和中药提取液,并搅拌3min,然后再依次往里加入依地酸二钠、氯化钠、甘氨酸、柠檬酸、柠檬酸钠,边加入边搅拌5min,全部溶解后再加入浸湿的活性炭,搅拌吸附20min后分别通过钛棒过滤器和过滤器进行脱碳和过滤处理;
S4、向配液罐分次加入注射用水,并不断搅拌,并将溶液的PH值调节至6.6~7.1,然后往灭菌过的不锈钢桶里加10L注射用水将甘草酸单铵盐S、盐酸半胱氨酸、无水亚硫酸钠溶解后加入稀配罐,最后用注射用水将溶液调整至220L,循环搅拌20min后将药液温度控制在30~40℃,并将药液的pH值调节至5.8~7.2,各项指标合格后向稀配罐中充氮气进行保护;
S5、将稀配处理后的药液通过除菌滤器过滤后,打入缓冲罐;
S6、通过灌装封口机对药液进行灌装封口处理,灌装封口的标准为2.05~2.15ml/支。
5.根据权利要求3所述的一种复方甘草酸单铵S注射液药物组合物的制备方法,其特征在于,步骤S1-S6的操作环境为:相对湿度:50~65%,温度:15~25℃;使用的注射用水在使用时需将温度维持在50~65℃。
6.根据权利要求3所述的一种复方甘草酸单铵S注射液药物组合物的制备方法,其特征在于,所述的复方甘草酸单铵S注射液药物组合物的包装规格为包装规格为2ml×10支/盒×400盒/箱;所述的过滤膜为的滤孔孔径为8~12μm。
7.根据权利要求3所述的一种复方甘草酸单铵S注射液药物组合物的制备方法,其特征在于,灌装指标合格的标准为:药液为无色的或淡黄色澄明液体,不得有见肉眼可见异物,甘草酸单铵盐的浓度为1.82~2.13mg/ml;甘氨酸的浓度为18.5~21.5mg/ml、盐酸半胱氨酸的浓度为1.50~1.65mg/ml。
8.根据权利要求3所述的一种复方甘草酸单铵S注射液药物组合物的制备方法,其特征在于,工序S3至工序S5需在12个小时内完成;工序S6需在10小时之内完成。
9.根据权利要求1-2任意一项所述的一种复方甘草酸单铵S注射液药物组合物用于制备急、慢性肝炎引起的肝功能异常和中毒性肝炎的辅助的治疗药物中的应用。
10.根据权利要求1-2任意一项所述的一种复方甘草酸单铵S注射液药物组合物用于食物中毒、药物中毒、药物过敏的药物中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810631103.6A CN108653667A (zh) | 2018-06-19 | 2018-06-19 | 一种复方甘草酸单铵s注射液药物组合物及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810631103.6A CN108653667A (zh) | 2018-06-19 | 2018-06-19 | 一种复方甘草酸单铵s注射液药物组合物及其制备方法和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN108653667A true CN108653667A (zh) | 2018-10-16 |
Family
ID=63776033
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810631103.6A Pending CN108653667A (zh) | 2018-06-19 | 2018-06-19 | 一种复方甘草酸单铵s注射液药物组合物及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108653667A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109364087A (zh) * | 2018-10-26 | 2019-02-22 | 山西普德药业有限公司 | 一种注射用复方甘草酸单铵s |
-
2018
- 2018-06-19 CN CN201810631103.6A patent/CN108653667A/zh active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109364087A (zh) * | 2018-10-26 | 2019-02-22 | 山西普德药业有限公司 | 一种注射用复方甘草酸单铵s |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102670864A (zh) | 治疗心脑血管疾病和糖尿病的抗氧化功能的药物组合物 | |
JP6605036B2 (ja) | 肝臓及び腎臓の損傷関連疾患を予防し又は治療する中医薬組成物の調製法 | |
CN103919854B (zh) | 密蒙花及其提取物在制备药物中的应用 | |
CN102309475A (zh) | 一种注射用左卡尼汀及其制备方法 | |
CN107417556A (zh) | L‑天门冬氨酸螯合钙及其制备方法 | |
CN108653667A (zh) | 一种复方甘草酸单铵s注射液药物组合物及其制备方法和应用 | |
CN102302502A (zh) | 一种复方甘草酸苷制剂及其制备方法 | |
CN104055935B (zh) | 一种协同提高免疫力的中药组合物 | |
CN103446166B (zh) | 肝功能改善剂 | |
CN106074464A (zh) | 大麻二酚在制备治疗痛风药物中的应用 | |
CN104013753B (zh) | 用于治疗骨关节炎的中药提取物及其制备方法 | |
CN106361983A (zh) | 一种辅助治疗糖尿病的胶囊剂及其制备方法 | |
CN110432492A (zh) | 一种降血糖的纳米包合物及其制备方法 | |
CN109985059A (zh) | 石斛多糖在制备癌症化疗后生殖损伤恢复药物中的应用 | |
CN104127473A (zh) | 一种治疗骨疾病的药物组合物及其注射剂和制法 | |
CN101023987A (zh) | 一种治疗变态反应性鼻炎的药物 | |
CN104547830B (zh) | 一种健脑口服液及其制备方法 | |
CN100382799C (zh) | 一种具有保肝作用的静脉注射用粉针及其制备与质量控制方法 | |
CN106880756A (zh) | 用于治疗性功能减退的中药组合物及其制备方法 | |
CN104055777B (zh) | 一种含有甲硫氨酸维b1的冻干药物组合物 | |
CN108553596A (zh) | 一种可缓解视疲劳的组合物及制备方法和应用 | |
CN109125413A (zh) | 一种具有补肾壮阳作用的中药组合物制剂及其制备方法 | |
CN109481464A (zh) | 一种注射用富勒烯乳剂及其制备方法 | |
CN103494978B (zh) | 使用芦荟、灵芝制备治疗肝腹水瘤的冻干粉针剂的方法 | |
CN102688277B (zh) | 一种用于除湿通痹的药物组合物、制剂及其制备与应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20181016 |